ABT 378/r: A novel inhibitor of HIV-1 protease in haemodialysis [5]

AIDS

Volumn 15, Issue 5, 2001, Pages 662-664

  Izzedine, Hassane ^a   Launay Vacher, Vincent ^a   Legrand, Mayeule ^a   Lieberherr, Deborah ^a   Caumes, Eric ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 378R; AMPHOTERICIN B; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE;

ADULT; AREA UNDER THE CURVE; CASE REPORT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; SIDE EFFECT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY FAILURE; LEISHMANIASIS; MALE; PYRIMIDINONES; RENAL DIALYSIS; RITONAVIR;

EID: 0035970695     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103300-00024     Document Type: Letter

References (4)

1. In vitro selection and characterisation of human immunodeficiency virus type 1 variants with increased resistance to ABT-378? A novel protease inhibitor
2. Effect of renal failure on drug metabolism by the liver
3. Plasma protein binding and distribution characterisrics of drugs as indices of their hemodialyzability
4. Drug dosage in patients during continuous renal replacement therapy